tbuckley/cabot-search huggingface dataset:
SAT0287 Factors Associated with Spine Strength Assessed by Finite Element Analysis of Clinical Computed Tomography Increase in Response to Daily Teriparatide Treatment in Patients with Rheumatoid Arthritis
Authors: K. Ono, S. Ohashi, H. Oka, Y. Kadono, T. Yasui, Y. Omata, N. Shoda, S. Tanaka
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> In rheumatoid arthritis (RA), the osteoclast pathway is activated by abnormal immune conditions accompanied by chronic inflammation, ultimately resulting in periarticular and systemic osteoporosis. These conditions expose patients to an increased risk of fracture. It is important to predict the effectiveness of anti-osteoporosis drugs early on in these patients. <h3>Objectives</h3> The purpose of this study was to investigate clinical factors associated with spine strength assessed by finite element analysis of clinical computed tomography (CT/FEA) increase to daily teriparatide (TPTD) treatment for 12 months. <h3>Methods</h3> A total of 29 RA patients were enrolled in this study. Patients were 68.0±7.9 years old, and the duration of symptoms was 12.2±8.7 years. All patients received TPTD for 12 months and changes in serum procollagen type 1 N-terminal propeptide (P1NP) were evaluated from baseline to 1, 3, 6, and 12 months. Bone mineral density (BMD), assessed by dual X-ray absorptiometry (DXA), and bone strength, assessed by quantitative computed tomography (CT), were determined at baseline and at 12 months. Nonlinear finite element analysis (FEA) was performed on CT to estimate spinal-predicted bone strength (PBS). We used multivariate logistic regression analysis to investigate clinical factors that may help predict changes in PBS. <h3>Results</h3> Most subjects showed moderate disease activity (mean baseline Disease Activity Scores assessing with 28 joints with CRP, 2.75±0.79). Patients had significantly greater levels of serum P1NP at all points measured. Mean values at baseline and at 12 months were 0.89 mg/cm<sup>2</sup> and 0.94 mg/cm<sup>2</sup> (p&lt;0.01) for BMD of the spine (median change, 6.3%), and 3508N and 4070N (P&lt;0.01) for PBS of the spine (mean change, 19.8%). Multivariate logistic regression analysis revealed that a significant indicator of a PBS increase at 12 months was a 1-month absolute change of P1NP. The cutoff value for absolute change was 74.8 mg/dL, and the odds ratio was 29.9 (95% confidence interval, 2.8-939.6) after adjusting for bisphosphonate administration, oral prednisolone dose, and age. <h3>Conclusions</h3> Our results showed that an absolute change in P1NP at 1-month was a useful predictor for increases in spine PBS. CT/FEA appears to detect the effects of TPTD more sensitively than DXA. <h3>Disclosure of Interest</h3> None declared
Hepatitis A outbreak in Bijeljina, Bosnia and Herzegovina, August 2012 - April 2013
Authors: Z Dakic, S Musa
Journal: Eurosurveillance (2013)

From August 2012-April 2013, an outbreak of hepatitis A with 28 laboratory-confirmed cases occurred in Bijeljina, Bosnia and Herzegovina. The index case was in a seven year old child from the local Roma community. Cases were 7-70 years old, 7-15 year-olds (9 cases) were the most affected age group. The event highlights the susceptibility of the population due to reduced hepatitis A virus circulation with consecutive lower immunity in the population in the past years.
PWE-345 Use of “villosity” to select individuals progressing to colonoscopy – an unreliable tool
Authors: A Buxton, JA Henry
Journal: Gut (2015)

<h3>Introduction</h3> The Bowelscope screening programme offers “one-off” sigmoidoscopy to individuals at the age of 55. Those deemed at high risk following sigmoidoscopy are referred for colonoscopy. An adenoma with a villous or tubulovillous component is deemed high risk and should instigate colonoscopy. Determining whether a polyp is tubular or tubulovillous is subjective and prone to inter-observer variation. The BCSP pathology guidelines state “it is accepted that a neoplastic villus almost defies definition”. This review was designed to explore the variability of reporting villous morphology in the national Bowel Cancer Screening Program (BCSP) screening centres in Yorkshire, Humber and North Eastern (Y, H and NE) regions and to investigate the level of agreement between individual BCSP pathologists. <h3>Method</h3> 32 consultant pathologists active in the BCSP in Y, H and NE region viewed H and E glass slides from 12 bowel cancer screening polyps and categorised each as tubular, tubulovillous or villous. Following viewing, each case was presented to the group with a brief discussion of the features. Pathologists then used individual electronic voting buttons to classify each case into one of the three categories. Following the workshop, lead pathologists at the BCSP screening units in the Y, H and NE region provided the relative proportions of tubular, tubulovillous and villous adenomas reported in their screening centre in the previous 12 months. <h3>Results</h3> The graph below shows the percentage of pathologists classifying each of the twelve polyps in one of the three categories. No single case achieved consensus, with many showing a spread of classification little better than chance. Agreement was best on whether a polyp was a pure villous adenoma or not. Across the Y, H and NE region the proportion of adenomas reported as “tubulovillous”, ranged from 5.5 to 25%, with a median of 17%. These figures may disguise more marked individual variation as the figures from each screening centre represent the combined output of multiple individual pathologists and multiple departments. Pure villous adenomas were rare, median 0.6% of all adenomas, range 0.1 to 1.8%. <h3>Conclusion</h3> Use of “villosity” to predict need for colonoscopy is prone to marked inter-observer variation. Using villosity may lead to unacceptable variation in colonoscopy rates with the potential for unpredictable overburden on resources. Better definitions of what constitutes a villus are required, along with training to improve consistency in recognition, before it can be used as a reliable risk predictor in a national screening program. <h3>Disclosure of interest</h3> None Declared.
X-Ray Diffractometric Analysis of L-Cystine Stones in 12 Patients
Authors: A. Babionitakis, C. Dimopoulos, A. Kyriakidis, D. Stokidis, A. Karayiannis, T. Markopoulos, S. Sideris, G. Kallistratos
Journal: European Urology (1983)
Human ecology and mental illness
Authors: C B Wilkinson, W A O'Connor
Journal: American Journal of Psychiatry (1982)

Psychiatrists and others in the mental health field have long been aware that forces within the surrounding social network effect both favorably and unfavorably the individual psyche and the course of mental illness, but the systematic use of such factors in therapy and prevention has awaited a model. The authors identify a beginning yet workable approach to what an APA task force termed "ecopsychiatry"; the model proposed is not that of traditional linear or cause-and-effect perspectives but is based on a systemic model derived originally form biological ecology.
THU0469 Potential Biomarkers of Diabetes-Associated Osteoarthritis: An Exploratory Study
Authors: I. Shirinskiy, O. Sazonova, N. Kalinovskaya, V. Shirinsky
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Diabetes-associated osteoarthritis has been proposed as a distinct OA phenotype. To date, this phenotype has not been thoroughly described both in terms of its clinical and laboratory manifestations. We hypothesized that patients with diabetes-associated OA might have changed biomarkers of cartilage destruction, autoimmunity, and DNA methylation. <h3>Objectives</h3> To evaluate concentrations of serum aggrecan, autoantibodies to collagen type II (anti-CII), and global DNA methylation in peripheral blood mononuclear cells (PBMC) in patients with diabetes-associated OA. <h3>Methods</h3> Sera and PBMC were obtained from 78 patients with diabetes-associated OA and 26 control OA patients. Circulating aggrecan and anti-CII levels were measured using commercial ELISA. To assess global PBMC methylation we measured nuclear 5-methylcytosine (5-MeC) using flow cytometry. <h3>Results</h3> Patients with diabetes-associated OA had significantly increased concentrations of serum aggrecan (p=0.004), and anti-CII (p=0.006). In comparison with OA alone, PBMC nuclear levels of 5-MeC were significantly increased (p=0.001) in patients with OA and diabetes. <h3>Conclusions</h3> Diabetes-associated OA is characterized by increased cartilage degradation, autoimmunity to CII, and elevated global PBMC methylation. These findings may provide further framework for studies on this OA phenotype pathogenesis. <h3>Acknowledgements</h3> We acknowledge Dr H. Trifonova for her help in collecting clinical data and laboratory samples handling. <h3>Disclosure of Interest</h3> None declared
Mouse Pox (Infectious Ectromelia)&lt;xref ref-type="fn" rid="FN1"&gt;1&lt;/xref&gt;
Authors: Leon Z. Saunders, DVM
Journal: JNCI Journal of the National Cancer Institute (1958)

Journal Article Mouse Pox (Infectious Ectromelia) Get access Leon Z. Saunders, DVM Leon Z. Saunders, DVM Brookhaven National Laboratory, Upton, Long Island, New York Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 20, Issue 5, May 1958, Pages 875–877, https://doi.org/10.1093/jnci/20.5.875 Published: 01 May 1958
Estrogen Therapy and Coronary-Artery Calcification
Authors: Howard N Hodis, Wendy J Mack
Journal: New England Journal of Medicine (2007)

To the Editor: In their article on the Women’s Health Initiative Coronary-Artery Calcium Study (WHI-CACS), Manson et al. (June 21 issue)1 provide insight into another mechanism by which estrogen therapy reduces coronary heart disease (CHD) in women who have undergone hysterectomy and who initiate such therapy close to menopause.2 The authors’ findings further support the hypothesis that early initiation of such therapy has a beneficial effect.3 For women under the age of 60 years, scientific evidence indicates that estrogen therapy is as efficacious in reducing CHD as are other primary prevention therapies, such as lipid-lowering drugs and aspirin, and is more effective in reducing total mortality.4 For women in this age group, estrogen therapy has a risk profile that is no greater than that of other medications used for primary prevention of CHD in women.4 Studies by the WHI, other randomized trials, and observational studies (including the WHI observational study) show significant trends toward a greater benefit with respect to total mortality and CHD with a longer duration of estrogen therapy.2,4 WHI-CACS was similar to the Estrogen in the Prevention of Atherosclerosis Trial5 in providing mechanistic evidence for a role of estrogen therapy in the prevention of CHD in postmenopausal women. WHI not only has confirmed the known benefits from observational studies but also has clearly shown the relative safety of estrogen therapy under randomized, controlled conditions in women under the age of 60 years (Table 1).2,4
Salmonella enterica serotype Oranienburg infections associated with consumption of locally produced Tyrolean cheese
Authors: F Allerberger, P Kreidl, M P Dierich, E Klingsbichel, D Jenewein, C Mader, D Khaschabi, M Schönbauer, C Berghold
Journal: Eurosurveillance (2000)

Sixteen culture confirmed cases of enteric infection with Salmonella enterica serotype Oranienburg were detected between August 10 and September 29 1999 in Tyrol (Austria). Ten of them suffered bloody diarrhoea and six were asymptomatic carriers. Intervie
A Serological Reaction in Malignancies<xref ref-type="fn" rid="fn1">2</xref>
Authors: Werner F. Eisenstaedt, M.D.
Journal: JNCI Journal of the National Cancer Institute (1954)

A Serological Reaction in Malignancies Get access Werner F. Eisenstaedt, M.D. Werner F. Eisenstaedt, M.D. Manor Hospital, Chicago, Ill. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 15, Issue 3, December 1954, Pages 439–448, https://doi.org/10.1093/jnci/15.3.439 Published: 01 December 1954 Article history Received: 14 June 1954 Published: 01 December 1954
Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma
Authors: Timothy F. Cloughesy, Joseph Landolfi, Daniel J. Hogan, Stephen Bloomfield, Bob Carter, Clark C. Chen, J. Bradley Elder, Steven N. Kalkanis, Santosh Kesari, Albert Lai, Ian Y. Lee, Linda M. Liau, Tom Mikkelsen, Phioanh Leia Nghiemphu, David Piccioni, Tobias Walbert, Alice Chu, Asha Das, Oscar R. Diago, Dawn Gammon, Harry E. Gruber, Michelle Hanna, Douglas J. Jolly, Noriyuki Kasahara, David McCarthy, Leah Mitchell, Derek Ostertag, Joan M. Robbins, Maria Rodriguez-Aguirre, Michael A. Vogelbaum
Journal: Science Translational Medicine (2016)

Toca 511 (vocimagene amiretrorepvec) is an investigational nonlytic, retroviral replicating vector (RRV) that delivers a yeast cytosine deaminase, which converts subsequently administered courses of the investigational prodrug Toca FC (extended-release 5-fluorocytosine) into the antimetabolite 5-fluorouracil. Forty-five subjects with recurrent or progressive high-grade glioma were treated. The end points of this phase 1, open-label, ascending dose, multicenter trial included safety, efficacy, and molecular profiling; survival was compared to a matching subgroup from an external control. Overall survival for recurrent high-grade glioma was 13.6 months (95% confidence interval, 10.8 to 20.0) and was statistically improved relative to an external control (hazard ratio, 0.45; P = 0.003). Tumor samples from subjects surviving more than 52 weeks after Toca 511 delivery disproportionately displayed a survival-related mRNA expression signature, identifying a potential molecular signature that may correlate with treatment-related survival rather than being prognostic. Toca 511 and Toca FC show excellent tolerability, with RRV persisting in the tumor and RRV control systemically. The favorable assessment of Toca 511 and Toca FC supports confirmation in a randomized phase 2/3 trial (NCT02414165).
Bony Metastases
Authors: M Glazer, V V Sagar
Journal: New England Journal of Medicine (1995)

Figure 1. The results of whole-body bone scintigraphy in a 58-year-old man who reported backache are shown. Plain bone films were unremarkable. Scintigraphy revealed numerous foci of increased uptake of tracer (“hot spots”), a finding consistent with metastatic disease. Focally increased uptake reflects increased osteoblastic activity associated with the attempted repair of diseased bone. Subsequent studies revealed the tumor to be prostate cancer.
FRI0370 Development of Two Novel Patient Reported Outcome (PRO) Measures: The Systemic Lupus Erythematosus (SLE) Symptom Severity Diary (SSD) and Sle Impact Questionnaire (SIQ):
Authors: S.D. Mathias, P. Berry, J. deVries, A. Askanase, K. Pascoe, H. Colwell, D. Chang
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> SLE symptoms can vary from day-to-day; current PRO measures are inadequate to capture daily symptom variability in a research setting. <h3>Objectives</h3> To develop two PROs for use in clinical research, suitable for patient completion at home using an electronic format (ePRO), to assess: 1) SLE symptoms; and, 2) SLE impact. <h3>Methods</h3> Following IRB approval, 6 US rheumatology practices enrolled SLE patients for face-to-face concept elicitation (CE) interviews about SLE. The SLE Symptom Severity Diary (SSD) and SLE Impact Questionnaire (SIQ) were drafted and cognitively debriefed (CD) with SLE subjects to evaluate content, clarity, and relevance. The tools were finalized following clinical input and a translatability assessment. <h3>Results</h3> 41 subjects completed CE interviews (95% female, 55% Caucasian, 25% African American, mean age 48 years, 46% with moderate/severe SLE). Common symptoms included fatigue (98%), joint pain (93%), rash (88%), joint stiffness (80%), swelling of feet/hands (80%), and cognitive/memory issues (63%). Subjects reported difficulty with chores/housework (61%), leisure activities (39%), driving (39%), and sleeping (39%). Concepts most frequently impacting functioning are summarized below. Eighteen subjects completed CD interviews (94% female, 61% African American, 39% Caucasian, mean age 51 years, 50% with moderate/severe SLE). Minor revisions were made for emphasis and redundant items were deleted based on the CD interviews. The final SSD contains 17 common SLE symptoms, uses an 11-point response scale ("0 = Absent/Did not have" to "10 = Worst Imaginable"), and a 24-hour recall period. The final SIQ contains 50 items with a 7-day recall and 5-point Likert response options ("Not At All" to "Very Much"), assessing ability to make plans, take care of yourself/others, leisure activities, social functioning, physical functioning, sleep, memory/cognitive issues, work, and emotional functioning. <h3>Conclusions</h3> The SSD and SIQ are comprehensive PRO questionnaires that may be useful to evaluate fluctuating patient symptoms and their impact on SLE patients9 lives. Measurement properties will be assessed in the near future. <h3>Acknowledgements</h3> The research presented in this abstract was funded by GlaxoSmithKline, USA. <h3>Disclosure of Interest</h3> S. D. Mathias Consultant for: GlaxoSmithKline, P. Berry Shareholder of: GlaxoSmithKline, Employee of: GlaxoSmithKline, J. deVries Shareholder of: GlaxoSmithKline, A. Askanase Consultant for: GlaxoSmithKline, K. Pascoe Shareholder of: GlaxoSmithKline, Employee of: GlaxoSmithKline, H. Colwell Consultant for: GlaxoSmithKline, D. Chang Shareholder of: GlaxoSmithKline, Employee of: GlaxoSmithKline
Psychopathology in patients with Wilson's disease
Authors: A Medalia, I H Scheinberg
Journal: American Journal of Psychiatry (1989)

The authors used the MMPI to assess psychopathology in neurologically impaired and neurologically asymptomatic patients with Wilson's disease. Neurologically impaired patients showed more psychopathology on the schizophrenia and depression scales and had a significantly higher rate of severe depression.
SP0240 Extracellular Vesicles – State of the Art of a New Paradigm in Biology
Authors: E.I. Buzas
Journal: Annals of the Rheumatic Diseases (2015)

Research in the past decades resulted in a new paradigm in cell-cell communication: extracellular extracellular vesicle mediated transfer of complex biological information between cells. Secretion of extracellular vesicles (including exosomes, microvesicles/microparticles and apoptotic bodies) is an evolutionarily conserved, universal active process of cells. Vesiculation is a significant adaptive cell response that regulates signaling by removal of receptors, signaling molecules and miRNAs. It represents a process that may rescues cell by removal of cellular components that may threat cellular viability (such as membrane attack complexes). Vesiculation (extracellular vesicle type secretion) enables efficient horizontal transfer of different types of biomolecules including nucleic acids (RNA and DNA) as well as bioactive protein complexes. Extracellular vesicles are potent conveyors of danger signals. Furthermore, they have been shown to be inducers of pro-inflammatory responses, and they carry cytokines as well as tissue degrading enzymes. Recent evidences show that extracellular vesicles may induce cellular responses in synergy with cytokines. Accumulating data suggest that extracellular vesicles may be strongly implicated in rheumatic diseases. Extracellular vesicles contain known autoantigens recognized in autoimmune diseases, they may contribute to presentation of autoepitopes in a cell-free manner and may substantially modulate immune functions. In this rapidly expanding field, however, attention has to be paid to factors that may confound the detection of extracellular vesicles. It is recommended to follow the minimal experimental requirements suggested recently by the International Society for Extracellular Vesicles. Importantly, extracellular vesicle research holds promise for the development of a new generation of diagnostic and therapeutic methods, and therefore this new paradigm in biology deserves increasing awareness in rheumatology <h3>Disclosure of Interest</h3> None declared
Clinical Application of Radiolabeled RGD Peptides for PET Imaging of Integrin α<sub>v</sub>β<sub>3</sub>
Authors: Haojun Chen, Gang Niu, Hua Wu, Xiaoyuan Chen
Journal: Theranostics (2015)

Molecular imaging for non-invasive assessment of angiogenesisis is of great interest for clinicians because of the wide-spread application of anti-angiogenic cancer therapeutics. Besides, many other interventions that involve the change of blood vessel/tumor microenvironment would also benefit from such imaging strategies. Of the imaging techniques that target angiogenesis, radiolabeled Arg-Gly-Asp (RGD) peptides have been a major focus because of their high affinity and selectivity for integrin αvβ3--one of the most extensively examined target of angiogenesis. Since the level of integrin αvβ3 expression has been established as a surrogate marker of angiogenic activity, imaging αvβ3 expression can potentially be used as an early indicator of effectiveness of antiangiogenic therapy at the molecular level. In this review, we summarize RGD-based PET tracers that have already been used in clinical trials and intercompared them in terms of radiosynthesis, dosimetry, pharmacokinetics and clinical applications. A perspective of their future use in the clinic is also provided.
PTH-050 Outcomes for emergency colectomy for inflammatory bowel disease over 14 years
Authors: R Mclean, M Jones, D Fung, S Dixon, P. McCallum, I O’Loughlin
Journal: Gut (2015)

<h3>Introduction</h3> Consideration of emergency colectomy in IBD is a common clinical situation in acute disease episodes facing gastroenterologists and surgeons. This study aimed to describe changes in incidence and outcomes in the last 14 years. <h3>Method</h3> Trust information departments at Newcastle upon Tyne and Gateshead Health foundation trusts were contacted to request data for all emergency admissions under a general surgeon from 2000–2014 after necessary approvals. Emergency colectomies for IBD were identified using ICD-10 codes K50 and K51; and OPCS-4 procedure codes H04–11, H29 and H33. Data on demographics, co-morbidities, interventions and outcomes were also collected and analysed. <h3>Results</h3> There were 208 emergency colectomies for IBD from a total of 1,275 emergency colectomies (16.4%); 130 for Crohn’s and 78 for UC. The mean age was 43.2 years (95% CI: 40.6 to 45.8 years), 52.4% of patients were men. Patients with Crohn’s were younger at resection (40 vs 48.6 years, p = 0.002) and came to resection more quickly from the time of admission (5.44 vs 8.61 days, p &lt; 0.001). The number of emergency colectomies for IBD were 54 in 2000–04, 95 in 2005–09, and 59 in 2010–14. There were 10 inpatient deaths postoperatively (4.8%), and these patients were significantly older (mean age 72.9 vs. 41.7, p &lt; 0.001) with more comorbidity (mean Charlson score = 10.3 vs. 1.51, p = 0.003). The mortality rate has fallen over the same period from 5.6% (00–04), 7.4% (05–09), to 0.0% (10–14). Mortality was significantly higher with delay to theatre, with those that died being operated on at 13.2 vs. 6.2 days (mean) from admission (p = 0.049) <h3>Conclusion</h3> Emergency colectomy mortality rates have fallen over the last 14 years. To improve survival further efforts must be made to identify patients requiring surgery sooner. The elderly and those with increased co-morbidity represent a particularly high risk group. <h3>Disclosure of interest</h3> None Declared.